January 15, 2025 10:33 AM ESTUpdated 01:00 PM
News Briefing

Hinge Bio's $30M raise; Keros re­ports ad­di­tion­al is­sues in Phase 2 PAH tri­al

ENDPOINTS

Plus, news about In­flam­ma­some Ther­a­peu­tics, John­son & John­son and Ve­rastem:

Au­toim­mune dis­ease start­up nabs $30M: Hinge Bio

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

#JPM25 live blog day 3: PhRMA chief on re­form­ing the IRA; Gilead weighs in on Chi­na deal­mak­ing

On­col­o­gy biotech plots ex­pe­dit­ed ap­proval for bone can­cer drug af­ter Phase 2 win

Ver­tex's bid to of­fer Cas­gevy fer­til­i­ty sup­port is 'self-serv­ing,' HHS says

BIO CEO plans to join FDA mod­ern­iza­tion ad­vi­so­ry board un­der Trump ad­min­is­tra­tion

FDA ex­plains why it re­ject­ed Van­da's stom­ach drug in late 2024

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

A service from the Financial Times